<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Nov. 14, 2019 (HealthDay News) — Neither vitamin D nor marine omega-3 (n-3) fatty acid supplementation significantly reduces the rate of first heart failure hospitalization, according to a research letter published online Nov. 11 in Circulation<\/i> to coincide with the annual meeting of the American Heart Association, held from Nov. 16 to 18 in Philadelphia.<\/p>\n
Luc Djouss\u00e9, M.D., Sc.D., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues examined the effects of vitamin D and n-3 supplements on the incidence of heart failure hospitalization in a large, multi-ethnic cohort with 25,871 adults; 36 participants with prevalent heart failure were excluded.<\/p>\n
The researchers found that first heart failure hospitalization occurred in 499 participants (240 events in the vitamin D group and 259 in the placebo group; hazard ratio, 0.96 [95 percent confidence interval, 0.78 to 1.11; P = 0.41] and 244 and 255 events in the n-3 and placebo groups, respectively; hazard ratio, 0.96 [95 percent confidence interval, 0.80 to 1.14; P = 0.61]). In a secondary analysis, rates of recurrent heart failure hospitalization did not differ between the vitamin D and placebo groups (341 versus 364 events; hazard ratio, 0.94; 95 percent confidence interval, 0.81 to 1.09; P = 0.44), while a significant reduction was seen with n-3 supplementation versus placebo (326 versus 379 events; hazard ratio, 0.86; 95 percent confidence interval, 0.74 to 0.998; P = 0.048).<\/p>\n
“Exploratory analyses suggesting some benefits of n-3 fatty acids on recurrent HF hospitalization require confirmation in future trials,” the authors write.<\/p>\n
Two authors disclosed financial ties to Quest Diagnostics, which measured serum 25-hydroxyvitamin D and serum omega-3 index at no cost; several pharmaceutical companies provided the study agents, matching placebos, and packaging.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n